Ophthalmology
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global ophthalmology drug development, market trends, and regulatory landscapes. Inform your pharma investment and BD strategy.
Showing 1–8 of 8 articles
Quick answer
NovaPharmaNews Ophthalmology hub for FDA covers 8 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Opus Genetics' OPGx-LCA5 Gene Therapy Accepted Into FDA's Rare Disease Evidence Program
Everads Therapy Publishes First-in-Human Clinical Data for Suprachoroidal Injector in Ophthalmology Science
Spinogenix Tazbentetol Shows Neuroprotective Effects in Glaucoma and Diabetic Retinopathy Preclinical Studies at ARVO 2026
Oculis to Present DME Research and Pipeline Updates at ARVO 2026 Annual Meeting
Outlook Therapeutics Completes FDA Dispute Resolution Meeting for LYTENAVA Bevacizumab Biosimilar
LENZ Therapeutics Submits VIZZ Presbyopia Treatment for UK Approval Following EU Validation
Glaukos Receives Permanent J-Code J2789 for Epioxa™ Ophthalmic Treatment, Effective July 2026
FDA Approves LumaGen Gene Therapy for Inherited Retinal Disease
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.